MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.14

-0.1%

10:04 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	7/23/2009 1:14:02 AM
	Read Replies (1) of 2240

So they are taken out just when they start developing an interesting pipeline of their own. Too bad. For the disappointed, there is still Genmab, which has access to most of the antibody technology of MEDX. Jason Genmab has a unique alliance with Medarex that gives us access to the UltiMAb® system for creating the full range of human antibody isotypes. Under this agreement, Genmab has the right to obtain licenses for an unlimited number of antibodies and owns the worldwide development and commercialization rights to these products. Genmab’s principal obligation under this agreement is to make royalty payments in connection with any such product licenses. Genmab received these rights in exchange for stock in the company, and we also received 16 fully paid up product licenses, which require no further payments to Medarex. In addition, in June 2001, we entered into a collaboration with Medarex to develop a human antibody to treat inflammation, HuMax-Inflam™ (now called HuMax-IL8™). In an asset exchange agreement in September 2007, Genmab gained full rights to HuMax-IL8.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next